The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksSymphony Env. Regulatory News (SYM)

Share Price Information for Symphony Env. (SYM)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 3.25
Bid: 3.00
Ask: 3.50
Change: 0.00 (0.00%)
Spread: 0.50 (16.667%)
Open: 0.00
High: 0.00
Low: 0.00
Prev. Close: 3.25
SYM Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Positive Coronavirus Test Results of d2p products

30 Nov 2020 07:00

RNS Number : 8376G
Symphony Environmental Tech. PLC
30 November 2020
 

 

 

 

The information communicated within this announcement is deemed to constitute inside information as stipulated under the Market Abuse Regulations (EU) No. 596/2014. Upon the publication of this announcement, this information is considered to be in the public domain

 

30 November 2020

SYMPHONY ENVIRONMENTAL TECHNOLOGIES PLC

("Symphony", the "Company" or the "Group")

 

Positive Coronavirus Test Results & Endorsement

of Symphony d2p Gloves & Facemask

Symphony Environmental Technologies Plc (AIM: SYM), a global specialist in technologies to enhance the properties of plastic and some non-plastic products, is pleased to announce that it has received further successful test reports from the Laboratory of Virology at the University of Campinas, Brazil ("Unicamp") on the Company's anti-viral nitrile gloves and polypropylene fabric facemasks, made with Symphony's d2pAM (antimicrobial) technology.

The gloves and facemasks were tested in accordance with ISO 21702-2019, the international standard for the measurement of anti-viral activity on plastics and other non-porous surfaces, against the Coronavirus strain MHV, genus Betacoronavirus (the same genus and family as SARS-CoV-1, SARS-CoV-2/COVID19 and MERS). The test reports concluded that "we recommend using d2pAM as a potential virucidal agent for the Coronavirus group and helps in controlling COVID-19."

The d2pAM glove showed a 99.99% virus-reduction after only one hour of contact. The d2pAM facemask showed a 99% virus-reduction after one hour of contact with the facemask, and 99.9% after two hours.

 

The same tests were performed on a glove and a facemask which did not contain d2pAM, and concluded that no virucidal effect was detected.

 

Symphony's CEO, Michael Laurier, said "These test results are a significant step forward in our global marketing campaign to promote the importance of using our d2p technology in these everyday essential products. We believe this is a major breakthrough in the fight against COVID. These masks and gloves will provide essential additional protection for everyone, especially for staff, patients, and visitors in a hospital or care-home environment.

 

The masks are already available in commercial volumes and, subject to securing manufacturing space, we hope to be able to supply the gloves during the second quarter of 2021 and will market both products through our global distribution network.

 

We are extremely pleased with this latest scientific validation of our d2pAM technology, but it is currently too early to estimate the level of demand for these products."

 

This announcement follows Symphony's d2p anti-bacterial bread bags being approved by the FDA in the US in February 2020, and after Eurofins Laboratories in August 2020 and Unicamp in September 2020 proving anti-viral efficacy on polyethylene film made with Symphony's d2pAM technology.

 

 

Information on Unicamp

https://www.timeshighereducation.com/world-university-rankings/university-campinas

 

 Enquiries

Symphony Environmental Technologies Plc

 

Michael Laurier, CEO

Tel: +44 (0) 20 8207 5900

Ian Bristow, CFO

 

www.symphonyenvironmental.com

 

 

 

Zeus Capital Limited (Nominated Adviser and Joint Broker)

 

David Foreman / Nick Cowles / Kieran Russell (Corporate Finance)

Tel: +44 (0) 161 831 1512

Dominic King / Victoria Ayton (Sales)

Tel: +44 (0) 203 829 5000

 

 

Hybridan LLP (Joint Broker)

Claire Louise Noyce

 

 

Tel: +44 (0) 203 764 2341

The person responsible for arranging the release of this information is Michael Laurier, CEO of the Company.

 

About d2p technology

Symphony has developed a range of additives, concentrates and master-batches marketed under its d2p® ("designed to protect") trademark, which can be incorporated in a wide variety of plastic and non-plastic products so as to provide protection against many different types of microbes, viruses and insects and rodents, and against fire. d2p products also include odour, moisture and ethylene adsorbers as well as other types of food-preserving technologies.

Symphony has also launched d2p anti-microbial household gloves and toothbrushes and is developing a range of other d2p finished products for retail sale. See www.d2p.net

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
MSCEAKFNAFXEFFA
Date   Source Headline
23rd Apr 20244:36 pmRNSHolding(s) in Company
19th Apr 202411:16 amRNSResult of GM
3rd Apr 20242:00 pmRNSDirector dealing
28th Mar 20244:23 pmRNSResult of PrimaryBid Offer
28th Mar 20242:18 pmRNSHolding(s) in Company
25th Mar 20243:02 pmRNSReplacement - Subscription and Notice of GM
22nd Mar 20247:01 amRNSPrimaryBid Offer
22nd Mar 20247:00 amRNSSubscription, PrimaryBid Offer and Notice of GM
14th Mar 20247:00 amRNSExtension to Convertible Loan Agreements
13th Mar 20247:00 amRNSUS Environmental Protection Agency positive report
9th Feb 20247:59 amRNSEU Judgment – Company Response
31st Jan 20249:48 amRNSEU Court Judgement
18th Jan 20247:00 amRNSTrading Update and EU Case
8th Jan 20247:00 amRNSGrant of options and PDMR dealing
2nd Jan 20247:00 amRNSDirector appointment & grant of options
28th Dec 20237:00 amRNSOptions amendments
18th Oct 20232:10 pmRNS£1.0m convertible loan agreement
29th Sep 20237:00 amRNSInterim Results
26th Sep 20237:00 amRNSYemen Enforces Oxo-Biodegradable Plastic Law
11th Aug 20237:00 amRNSDirectorate Change
1st Aug 20237:00 amRNSPre-close Trading Update
4th Jul 20237:00 amRNSDirectorate Change
29th Jun 20231:46 pmRNSResult of AGM
29th Jun 20237:00 amRNSAGM Statement
7th Jun 20238:34 amRNSPosting of Annual Report & Accounts & AGM Notice
30th May 20237:00 amRNSPreliminary Results
21st Mar 20237:00 amRNSEU court hearing
13th Mar 20233:40 pmRNSConvertible loan agreement & revenue update
9th Mar 20237:00 amRNSd2w BioBottles supply agreement with TricorBraun
23rd Dec 20227:00 amRNSTrading update
31st Oct 20227:00 amRNSAttendance at world’s leading plastics trade fair
28th Oct 20222:51 pmRNSDirector/PDMR Shareholdings – Option amendments
29th Sep 20229:00 amRNSInvestor Presentation
29th Sep 20227:01 amRNSSymphony India operations update
29th Sep 20227:00 amRNSInterim results for the 6 m/e 30 June 2022
9th Aug 20227:00 amRNSMexican Technical Standard Validating d2w
8th Aug 20227:00 amRNSAgreement for Middle East manufacturing
1st Aug 20227:01 amRNSEquity subscription and grant of warrants
1st Aug 20227:00 amRNSTrading Update
7th Jul 20227:00 amRNSd2p Anti-Insect Sales
29th Jun 20222:00 pmRNSResult of AGM
29th Jun 20227:00 amRNSAGM Statement
28th Jun 20227:00 amRNSd2p Supply Agreement with Grupo Bimbo
27th Jun 20227:00 amRNSPeru legal action outcome
7th Jun 20227:00 amRNSPosting of Annual Report and Notice of AGM
18th May 20227:00 amRNSAppointment of Executive Director
4th May 20227:00 amRNSGrant of Options
20th Apr 20227:00 amRNSSymphony India Sustainability Award
30th Mar 20227:00 amRNSPreliminary results
24th Feb 20223:49 pmRNSExtension of options

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.